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Together with Chromogranin B and Secretogranins, Chromogranin A (CGA) is stored in
secretory (chromaffin) granules of the diffuse neuroendocrine system and released with
noradrenalin and adrenalin. Co-stored within the granule together with neuropeptideY,
cardiac natriuretic peptide hormones, several prohormones and their proteolytic enzymes,
CGA is a multifunctional protein and a major marker of the sympatho-adrenal
neuroendocrine activity. Due to its partial processing to several biologically active peptides,
CGA appears an important pro-hormone implicated in relevant modulatory actions on
endocrine, cardiovascular, metabolic, and immune systems through both direct and
indirect sympatho-adrenergic interactions. As a part of this scenario, we here illustrate
the emerging role exerted by the full-length CGA and its three derived fragments,
i.e., Vasostatin 1, catestatin and serpinin, in the control of circulatory homeostasis
with particular emphasis on their cardio-vascular actions under both physiological and
physio-pathological conditions. The Vasostatin 1- and catestatin-induced cardiodepressive
influences are achieved through anti-beta-adrenergic-NO-cGMP signaling, while serpinin
acts like beta1-adrenergic agonist through AD-cAMP-independent NO signaling.
On the whole, these actions contribute to widen our knowledge regarding the
sympatho-chromaffin control of the cardiovascular system and its highly integrated
“whip-brake” networks.
Keywords: Chromogranin A, Vasostatin 1, Catestatin, Serpinin, adreno-sympathetic control, cardioprotection,
vasoactive peptides, endothelial signaling
INTRODUCTION
The granins are a structurally and functionally related family
of proteins including Chromogranin A (CGA), Chromogranin
B (CGB) and Secretogranins (SG) II-VII which are stored in
secretory (chromaffin) granules of the diffuse neuroendocrine
system and released together with noradrenalin and adrenalin
(Winkler and Fischer-Colbrie, 1992; Montero-Hadjadje et al.,
2008; Bartolomucci et al., 2011). Detailed information on chro-
mosomal positions, genomic structure, cDNA, and proteins
encoded by their three paralogous genes, that likely arose by gene
duplication within the vertebrate lineage, has been reported by
Mahata et al. (1996), Zhang et al. (2011) and Bartolomucci et al.
(2011). The adrenal medulla and the adrenergic terminals are a
main source of granins which are therefore been employed as
markers of the sympatho-adrenal neuroendocrine (SAN) activ-
ity. Granins within the vesicle stabilize the core osmotically by
binding catecholamines (CAs) and ATP, and are also co-stored
with neuropeptide Y (NPY), the cardiac natriuretic peptide hor-
mones (NPs), several prohormones and their proteolytic enzymes
(Videen et al., 1992). Their partial processing to biologically active
fragments together with milieu acidification contribute to the
maturation of the granule. The mechanisms of granin sorting
into regulated secretory pathway granules, including the CGA
domains that are required for directing it into the secretory gran-
ules, as well as the CGA N- and C-terminus that may have
targeting information, have been summarized by Bartolomucci
et al. (2011). Among granins, the soluble acidic 439- residue long
CGA is the most abundant protein of the granule, accounting for
almost 50% of its soluble protein content, and is the most studied
member, being considered the major indicator and multifunc-
tional effector of the SAN tone (Cryer et al., 1991; O’Connor et al.,
2008). Its wide spectrum of biological and physio-pathological
activities ranges from intracellular to organ and system levels.
A fundamental intracellular function of CGA is its granulo-
genic role in the formation of dense core secretory vesicles in
(neuro) endocrine cells (Kim et al., 2001; Kim and Loh, 2006).
In fact, CGA depletion by gene targeting causes reduction of
adrenal chromaffin granules in number, size, and electron density,
as well as disruption of transmitter secretion from the regulated
pathway (Mahapatra et al., 2005). Together with other granins,
CGA binds to the inner layer of the vesicle membrane affecting
the release of calcium from secretory granules to the cytoso-
lic exocytotic machinery through the inositol 1,4,5-trisphosphate
receptor/Ca2+ channel (Yoo et al., 2002). CGA has a long evo-
lutionary history and CGA-like proteins have been detected in
mammals, birds, amphibians, fish (including CGA mRNA in
zebrafish) and arthropods (Xie et al., 2008). In addition to
its expression in the neuroendocrine cells, as detailed below,
CGA has also been detected in other cell types, including the
myocardiocytes of various vertebrate species, e.g., amphibians
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(Krylova, 2007), rodents (Steiner et al., 1990; Biswas et al., 2010;
Pasqua et al., 2013) and humans, particularly in patients affected
by cardiomyopathy and heart failure (HF: Pieroni et al., 2007). In
normal conditions, upon stimulation of regulated secretion, CGA
is exocytotically released in the extracellular space and then in the
circulation, thus being able to exert systemic and/or organ and
tissue modulatory effects (Helle et al., 2007; Bartolomucci et al.,
2011; Angelone et al., 2012a and references therein). These actions
are mainly related to the prohormone/cytokin ability of CGA to
undergo a finely regulated clevage. That is, following stimulus-
and differential cell-type-specific or tissue-specific proteolytic
processing at dibasic sites, CGA generates within secretory vesi-
cles several peptides in aggregate which can then exert relevant
modulatory actions on endocrine, cardiovascular, metabolic, and
immune systems through both direct and indirect SAN interac-
tions (Metz-Boutigue et al., 1993; Parmer et al., 2000; Taupenot
et al., 2002). The CGA biologically active fragments include the
amino terminal cardio and vasoactive vasostatin 1 (VS-1), the
antimicrobial chromacin, the dysglicemic peptide pancreastatin
(PST), the parathormon release modulator parastatin, the cat-
echolamine release inhibitor catestatin (CST), and the recently
discovered serpinin (see Figure 1).
With reference to the cardiovascular focus of this review, we
will illustrate the actions of both circulating CGA and its three
fragments, VS-1, CST and serpinin (Tota et al., 2010, 2012), which
exert a broad spectrum of regulatory influences on the cardio-
circulatory system. Although nothing is known on how these
activities and the underpinning proteolytic events are spatio-
temporally coordinated, it is conceivable that both the systemic
actions of CGA and those induced by the CGA-derived pep-
tides at organ/tissue (heart and vessels) level may be synergically
implicated in circulatory homeostasis, coordinating and coun-
teracting SAN overactivity under normal and perturbed condi-
tions. Namely, these substances can operate as “integral” con-
troller components, bringing the controlled variable back to set
“point” at any steady-state disturbance, according to the Koeslag
et al.’s (1999) concept of the “zero steady-state error” homeosta-
sis achieved by pairs of counter-regulatory hormones (originally
applied for CST and PST). Before discussing this issue, for the
non-expert reader we will very briefly summarize the physio-
pathological implications of heightened SAN activity.
PHYSIO-PATHOLOGICAL ASPECTS OF SAN
OVERACTIVATION
There is a wide spectrum of SAN-induced actions on the cir-
culation, ranging from blood coagulation, platelet adhesiveness,
smooth muscle cell hyperplasia, arterial wall tone, hyperlipi-
demia, denervated myocardium etc. to immunologic responses in
relation to cardiovascular changes. Therefore, it is not surprising
that SAN overstimulation (the “adrenergic storm”) may act on
a number of different targets, directly impinging the heart and
the vasculature. The corresponding physio-pathological changes
have long been known, ranging from the experimental necrotic
damage induced by CAs in the rodent heart (Samuels, 2007)
to the extensive clinical evidence showing that the initial heart
response to prolonged SAN overactivity leads to compensatory
remodeling, cardiac hypertrophy and, if the stress will over-
whelm the system, HF (Chien et al., 1991 and references therein).
If left uncontrolled, the SAN overactivation may result to be
more deleterious than the actual stress placed on the heart. In
human HF, chronic heightened adrenergic activation, mainly via
CAs signaling, has adverse prognostic significance, accelerating
FIGURE 1 | This synopsis illustrates Chromogranin-A (CgA) processing and biological activities which are reviewed in this volume (modified from
Angelone and Tota, 2012). This provides a cardiovascular dimension for CgA, with important outcomes in terms of biology, physiology and clinics.
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the pathological processes (Cohn and Yellin, 1984). Apart from
being of clinical relevance, these cardiovascular studies have pro-
vided the rationale for anti-adrenergic drug therapy, including the
beta-adrenergic-blockers, still amongst the most used drugs. The
growing evidence regarding the emerging cardiovascular role of
CGA and CGA-derived VS-1, CST and serpininmay represent the
next breakthrough in this field (see Figure 2).
THE CARDIO-CIRCULATORY PROFILE OF FULL-LENGTH CGA
Circulating CGA (normal values: 0.5–2 nM: Helle et al., 2007;
Crippa et al., 2013) increases under conditions of stress-elicited
SAN over-activation and physio-pathological conditions, e.g.,
chronic inflammation, neuroendocrine tumors, acute coronary
syndromes and chronic HF. Therefore, CGA plasma levels have
been used as prognostic indicators in these conditions (Helle
et al., 2007; Angelone et al., 2012a; D’amico et al., 2014). It is
important to note that pertinent information on plasma levels of
CGA and its derived peptides can be best obtained by serologi-
cal studies that in addition to processing-independent radioim-
munoassays include also region-specific processing-dependent
assays. In fact, only the latter can allow to analyse the plasma
levels of the various granin-derived fragments which exhibit rele-
vant and sometime opposite biological functions and prognostic
significance (Crippa et al., 2013; Goetze et al., 2014). The CGA
in vivo long half-life (∼18min) and its relatively elevated circu-
lating concentrations (also under normal conditions), reduce the
possibility of false measurements and facilitate blood collection,
pre-analytic handling and final determinations (O’Connor et al.,
1989).
Plasma CGA concentrations are increased up to 10–20 nM
(500–1000 ng/ml) in patients with essential hypertension
(Takiyyuddin et al., 1995), myocardial infarction (Omland et al.,
2003), acute destabilized HF (Dieplinger et al., 2009), acute
coronary syndromes (Jansson et al., 2009), chronic HF (Ceconi
et al., 2002) and decompensated hypertrophic cardimyopathy
(Pieroni et al., 2007). As firstly documented by Ceconi et al.
(2002), circulating CGA levels significantly parallel the severity
of the dysfunction, representing an independent predictor for
mortality. Accordingly, from a clinical point of view, CGA is
now emerging as a potentially new diagnostic and prognos-
tic cardiovascular biomarker independent from conventional
markers.
Studies in twins indicated that basal plasma CGA concentra-
tion is highly heritable (Takiyyuddin et al., 1995). Compared with
age-matched normotensive counterparts, patients with essen-
tial hypertension show increased plasma CGA and an increased
release of stored CGA in response to adrenal medullary stim-
ulation by insulin-evoked hypoglycemia (Takiyyuddin et al.,
1995). Among others, these observations confirm the correlation
between CGA and SAN activity.
A relevant circulatory function of CGA is related to the reg-
ulation of endothelial barrier (Ferrero et al., 2004) and tumor-
induced vascular remodeling (Veschini et al., 2011). Both CGA
and VS-1 are potent inhibitors of the proangiogenic Vascular
Endothelial Growth Factor (VEGF), as well as the thrombin-
induced endothelial cell permeability (Ferrero et al., 2004)
and inhibit the TNF-elicited changes on endothelial cells, i.e.,
gap formation, disassembly of vascular endothelial-cadherin
FIGURE 2 | Schematic representation of the possible sites for
intervention of CgA and its derived peptides in heart failure.
CgA and its fragments could operate at two, non-exclusive, levels:
systemic and local. At the systemic level, CgA may work together
with other factors (catecholamines, ANGII, cytochines, chemochines,
etc) in the stress response, as in the case of the neuroendocrine
scenario activated in CHF. At the local (heart) level, systemic and/or
intracardiac physical and chemical stimuli could trigger CgA
processing to generate cardioactive peptides, i.e., VSs, CST, serpinin
(modified from Angelone et al., 2012a).
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adherence junctions and vascular leakage (Ferrero et al., 2004;
Dondossola et al., 2011). Systemic administration of CGA (1μg)
to lymphoma-bearing mice potently reduces the TNF-elicited
penetration of a synthetic dye (patent blue) in tumor tissues
(Dondossola et al., 2011), confirming previous observations that
CGA can affect host/tumor interactions (Colombo et al., 2002).
Recently, Crippa et al. (2013) have reported in healthy sub-
jects the presence of biologically relevant plasma levels of full-
length CGA, CGA 1–76 (antiangiogenic) and fragments lacking
the C terminal region (proangiogenic) and have demonstrated
that blood coagulation triggers a thrombin-dependent almost
complete conversion of circulating CGA into fragments lacking
the C- terminal region. This uncovers a novel role of CGA as
an angiogenesis activator which, under conditions of perturbed
angiogenesis (wound healing, cancer, etc.), can contribute to
circulatory and vascular homeostasis through the opposite angio-
genic effects of its fragments (possibly VS-1 and CST) generated
by tightly spatio-temporally regulated proteolysis.
A similar modulatory strategy exerted by CGA has been sug-
gested at the heart level on the basis of morphological, biochem-
ical and physio-pharmacological evidences briefly summarized
below.
THE INTRACARDIAC LOCALIZATION OF CGA
Using immunohistochemical technique, Steiner et al. (1990)
demonstrated in the myoendocrine granules of the rat heart the
co-localization of CGA and ANP. Their immunoblotting finding
suggested amore extensive myocardial CGA processing compared
to that of the adrenal medulla. As remarked by Miserez et al.
(1992), an additional source of cardiac CGA and/or CGA-derived
fragments may result from the nerve termini innervating the
heart. Weiergräber et al. (2000) showed that CGAwas also present
in rat Purkinje conduction fibers, in both rat atrium and ventri-
cle, as well as in H9c2 rat cardiomyocytes. More recently, Biswas
et al. (2010) confirmed the presence of CGA, as well as that of
CGB and SG in the secretory granules of the mouse myocardium.
Importantly from a physio-pathological point of view, Pieroni
et al. (2007) provided immunohistochemical evidence of CGA-
positive intracellular staining in the human myocardium. They
used confocal microscopy to show that in ventricular car-
diomyocytes of dilated and hypertrophic human hearts CGA is
colocalized with Brain Natriuretic Peptide (BNP). RT-PCR cor-
roborated this finding documenting the myocardial presence of
CGA-mRNA, while ELISA assays with four different monoclonal
antibodies allowed to measure more than 0.5μg of CGA per
gram of left ventricular myocardial tissue. Assuming a constant
myocardial release of CGA and considering that the plasma half-
life of CGA is 18.4min Corti et al. (1996), Pieroni et al. (2007)
postulated a significant cardiac contribution to the increased
circulating CGA levels reported in their patients. The possible
correlation of CGA with the NPs system could contribute to
regulate cardiovascular function through short- and long-term
depressing influences, inducing tonic vasodilation, hypotension
and cardioprotection against adreno-sympathetic hyperactiva-
tion. Moreover, because of the strong association between plasma
CGA/NPs concentrations and the degree of hemodynamic dys-
function in HF, both hormones have been used as promising
prognostic indicators of the severity of HF (see Dieplinger et al.,
2009 and references therein). Furthermore, the significant corre-
lation between CGA levels and left ventricle end diastolic pressure
may implicate for myocardial CGA the operation of stretch-
elicited release and transcriptional up-regulation mechanisms
similar to that reported for BNP (Tota et al., 2010 and references
therein).
In the rat heart, intracardiac presence and processing of CGA
were biochemically demonstrated by Glattard et al. (2006). By
submitting the RPHPLC purified CGA-immunoreactive frac-
tions from cardiac extracts to western blot and MS anal-
ysis (TOF/TOF technique), the authors characterized four
endogenous N terminal CgA-derived peptides, i.e., CGA4–113,
CGA1–124, CGA1–135 and CGA1–199, containing the VSs
sequence. The intact CGA was also detected among these and
other C-terminal truncated fragments. It is important to note
the cell-specific feature of this proteolytic CGA fragmentation,
as contrasted by the rat adrenal gland in which almost no intact
CGA is found; on the other hand, pancreatic beta cells produce
betagranin corresponding s to the N-terminal portion of CGA
(Hutton et al., 1987). The comparison of these and other obser-
vations seems to indicate that in the heart the maturation process
can be incomplete and specific. It is of particular interest the find-
ing, more recently confirmed by Pasqua et al. (2013), that the
cardioactive motif (the VS-1 sequence or a portion of it) is present
among the low-molecular-mass fragments identified. Therefore,
the possibility exists that, under normal or stressfull conditions
the heart responds to a specific physical (e.g., stretch) or chemical
(e.g., CAs) stimulus activating proteolytic CGA processing with
subsequent increase in lower-molecular-mass cardioactive frag-
ments. This supports our working hypothesis (Pasqua et al., 2013,
and references therein) that CGA, in addition to its endocrine and
systemic role, can exert a direct autocrine/paracrine modulation
on the heart.
PHYSIO-PHARMACOLOGICAL EVIDENCE OF DIRECT CGA
CARDIOACTIVITY
Using isolated and Langendorff perfused hearts of normotensive
and spontaneously hypertensive rats (SHR), Pasqua et al. (2013)
have shown for the first time that the exogenous full-length CGA
(1–4 nM) directly affects myocardial contractility and coronary
vasomotion (dilation) by Akt/NOS/NO/cGMP/PKG pathway. At
the same time, the rat heart in response to hemodynamic and
chemical (β-adrenergic and ET-1) excitatory stimuli generates
CGA fragments, including the cardioactive VS-1. Therefore, this
evidence, which conceptually interlocks the systemic (endocrine)
and intracardiac (paracrine/autocrine) actions of full-length CGA
and its derived cardioactive peptides, provides a rationale for
future investigations on the putative multilevel switches of the
SAN/CGA axis that may operate under normal and physio-
pathological conditions. In this perspective, here below we will
briefly illustrate the cardiovascular profiles of VS-1, CST and ser-
pinin, that have been documented in rodent heart preparations.
For space economy, we will not discuss the cardiac effects that VS-
1 and CST exert on cold vertebrate hearts (frog and eel) which
confirm the peptide profiles observed in the rodent heart (see for
references, Tota et al., 2010). Our aim is to highlight the intriguing
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characteristics of a protein like CGA which has revealed itself to
function both as a pleiotropic hormone and a cytokine.
CARDIAC ACTIONS OF VS-1
Numerous studies conducted by our group have demonstrated
that the N terminal human recombinant (hr) CGA-derived
fragments VS-1 (hrCGA1–78) and VS-2 (hrCGA 1–113), as
well as the corresponding fragments from bovine CGA and
rat CGA (rCGA1-64), exert relevant cardiodepressive and anti-
adrenergic influence on several vertebrate (rat, frog and eel) heart
preparations (reviewed by Tota et al., 2010). Both VS-1 and
VS-2 concentration-dependently inhibit myocardial contractil-
ity (negative inotropism) and relaxation (negative lusitropism),
thus directly modulating the mechanical performance of intact
isolated and perfused hearts beating under basal, i.e., non-
stimulated, and adrenergically stimulated, conditions (Tota et al.,
2010). Since the VS-1-elicited cardiotropism resulted more
relevant than that of VS-2, here we will only focus on VS-1.
The isolated Langendorff-perfused rat heart was used to
analyse in detail the VSs influence on myocardial contrac-
tility (Cerra et al., 2006). In particular, hrCgA 1–78, con-
taining the VS-1 (CgA 1–76) sequence, at all concentrations
tested (11–165 nM) under basal conditions dose-dependently
depressed both contractile activity and cardiac work, as indi-
cated by the decrease of left ventricular pressure (LVP) and
rate pressure product (RPP: HRx LVP), respectively. No effect
on coronary vasomotion was detected, as indicated by the
unchanged coronary pressure (CP). Noteworthy, as shown by
Pieroni et al. (2007) on the isolated Langendorff rat heart,
hrVS-1 is also a negative lusitropic agent since concentration-
dependently it decreases myocardial relaxation, i.e., it reduces
the maximal rate of the left ventricular pressure decline of LVP
[−(LVdP/dt)max], the half time relaxation (HTR), and T/−t
ratio obtained by +(LVdP/dt)max/−(LVdP/dt)max. The peptide
counteracted the β-adrenergic (Isoproterenol, ISO)-induced pos-
itive inotropic and lusitropic effects through a non-competitive
mechanism. Taken together, these peptide-induced actions point
to VS-1 as a relevant modulator of rat heart mechanical per-
formance under basal and adrenergically stimulated conditions.
However, these findings beg the question as to whether or not
the peptide-elicited cardiac effects are species-specific. To clarify
this issue, using rat cardiac preparations (the isolated Langendorff
perfused heart and the papillary ventricular preparation), Cerra
et al. (2008) analyzed the cardiac actions of the native (rat) CGA
1-64 (rCGA1-64), i.e., a highly conserved cleavage N-terminal site
that reproduces the native rat sequence, corresponding to human
N-terminal CGA-derived VS-1 (Metz-Boutigue et al., 1993; Helle
et al., 2007). Of note, the concentrations used were the same
of its precursor, CGA, in the human serum (i.e., normal levels:
0.5–4 nM, neuroendocrine tumors and last stages of chronic HF:
>10 nM) (Helle et al., 2007). The study not only confirmed that,
the rCgA1-64 fragment from 33 to 165 nM elicited a significant
negative inotropic and lusitropic effects without modifying HR,
but also demonstrated that the peptide was a coronary vasodila-
tor, as indicated by a significant reduction of CP. Accordingly,
this vasoactivity, for the first time detected on an intact whole
coronary bed, further corroborated the “vasostatin” (ad litteram)
profile of this fragment, as previously reported on segments
of bovine coronary resistance arteries, intrathoracic artery and
saphenous vein exposed to the hrCgA 1–78 active domain 1–40
(Brekke et al., 2002). The absence of coronary activity of the
human recombinant hrCgA1-78, previously evidenced by Cerra
et al. (2006), suggests that distinct species-specific sensitivities of
the vascular tissues toward VS peptides may account for these
different responses. This, however, does not appear to be the
case of the myocardium, since the comparison of the contractile
effects of rCGA 1-64 and hrCGA1-78 highlights their substan-
tial similarity. This suggests that the rat heart may be a useful
model for medically-oriented studies regarding the potential of
VS−1as a therapeutic agent. The treatment with rCGA65-76
did not modify cardiac performance at all concentrations tested,
except for a small chronotropic effect from 11 to 110 nM, and did
not modify the β-adrenergic (ISO)-induced intrinsic activity. An
important characteristic of rCGA 1-64 is its ability to counteract
ISO (1μM)- and endothelin 1 (ET-1)-elicited positive contrac-
tility, as well as the potent ET-1-induced coronary constriction.
Experiments on isolated papillary muscles, i.e., an experimental
model in which contractility is analyzed independently from HR
and coronary flow, confirmed that the peptide depresses basal and
ISO-elicited contractility, without affecting calcium transients on
isolated ventricular cells.
The analysis of the percentage of variations of LVP, which
provides the EC50 values in the presence of either increasing con-
centrations of ISO alone or of ISO plus rCGA 1-64 (11, 33, and
65 nM), showed that rCGA1-64 elicits its anti-β-adrenergic action
through a functional non-competitive antagonism, confirming
the results obtained with the human VS-1 (Cerra et al., 2006).
Furthermore, to have an insight on structure-function rela-
tionship, three modified peptides were tested on both rat heart
and papillary muscles, showing that the di-sulfide bridge was
necessary for the cardiac activity.
In the heart, similarly to the hrVS-1 signal-transduction (Cerra
et al., 2006), the rCGA1-64 signals through a Gi/o protein-PI3K-
NO-cGMP-PKG-dependentmechanism. In particular, as clarified
by the results obtained on the isolated papillary muscle, the action
mechanism appears to implicate a calcium-independent/PI3K-
dependent NO release by endothelial cells. In fact, rCGA1-64, had
no effect on intracellular calcium concentration in isolated ven-
tricular cells, but elicited NO release from cultured bovine aortic
endothelial cells (BAE-1) through a calcium-independent mech-
anism. The eventual involvement of the endocardial endothelium
in this mechanism remains to be evaluated. The evidence that
the rCGA1-64-induced coronary dilation is also abolished by
inhibitors of the NO-cGMP-PKG pathway suggests the likely
endothelial release of vasodilator autacoids such as NO.
The control of the NO/NOS system on myocardial contractil-
ity and its common tonic depressive influence have been exten-
sively documented. In the ventricular myocardium of the rat
NOS-generated NO depresses contractility through sGC-PKG
mechanism which decreases L-type Ca2+ current (Abi-Gerges
et al., 2001) and troponin I phosphorylation (Hove-Madsen et al.,
1996). Calcium-independent eNOS activation has been shown to
take place after stimulation of endothelium with insulin, insulin-
like growth factor-1 (IGF-1) and estrogens (Hartell et al., 2005)
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through the possible involvement of Akt dependent NOS phos-
phorylation (Shaul et al., 2002). Conceivably, our experiments
on papillary muscles and on BAE-1 cells treated with the
PI3K inhibitor wortmannin strongly suggest that the rCGA1-
64-elicited NO synthesis depends on PI3K activation. Maniatis
et al. (2006) have proposed a calcium-independent mechanism of
eNOS activation involving caveolae-mediated endocytosis elicited
by the albumin-binding protein gp60 and activation of down-
stream Src, Akt and PI3K pathways. It has been hypothesized
that VSs may interact with caveolar domain (see for references,
Tota et al., 2007), and that endothelial cells internalize CGA1-
78 (Ferrero et al., 2004). Therefore, it is possible that a similar
mechanismmay explain VS-1 dependent NOS activation in BAE-
1 cells, an issue that needs further research. On the whole, these
results strongly support our hypothesis (Tota et al., 2008, 2010)
that in the rat heart VS-1, and particularly the homologous
rCGA1-64 fragment may act as an autocrine/paracrine modu-
lator of myocardial and coronary performance, functioning as
homeostatic stabilizer against heightened SAN tone.
CARDIAC ACTIONS OF CST
CST was initially identified as the most potent endogenous
antagonist of nicotinic-cholinergic receptor (nAChR), exerting
antagonistic inhibition of nicotine-evoked CAs secretion in a
non-competitive way (Mahata et al., 1997). However, it has
revealed itself to act as a multifunctional peptide with different
action mechanisms. The in vitro and in vivo vasoactive and rel-
evant anti-hypertensive properties of CST have been extensively
reviewed (e.g., Mahata et al., 2010) and will not be considered
here.
The cardiotropic actions of wild-type CST (WT-CST, human
CGA352-372) and its naturally occurring variants (G364S-
CST and P370L-CST) were demonstrated for the first time by
Angelone et al. (2008) who used the isolated and Langendorff
perfused rat heart to evaluate the peptide-induced cardiac effects
independently from the minute-to-minute control exerted by
SAN over cardiac output (CO) and vascular tone. WT-CST (from
11 to 200 nM) dose-dependently decreased left ventricular pres-
sure (LVP, index of contractility), rate pressure product (index
of cardiac work) and both positive and negative LVdP/dt (index
of maximal rate of left ventricular contraction and relaxation,
respectively), while increased CP. While G364S-CST was ineffec-
tive on basal mechanical performance, P370L-CST elicited only a
negative inotropism. Human CST variants counteracted the pos-
itive β-adrenergic (ISO)-induced inotropic and lusitropic effects
with different rank order of potency (for the ISO-induced positive
inotropism: WT-CST>G364S-CST>P370L-CST; for the ISO-
induced positive lusitropism: G364S-CST>WT-CST>P370L-
CST (Angelone et al., 2008). In both the isolated Langendorff
rat heart (Angelone et al., 2012b) and in rat papillary muscle
(Bassino et al., 2011), CST before eliciting these major pro-
longed myocardial actions, induced an early transient positive
inotropic effect that disappeared after 5min from administra-
tion. This effect was mediated by H1 histamine receptors, since
it was abolished by H1 blockade, consistent with previous evi-
dence that in the rat the activation of myocardial H1 receptors
mediates the histamine-dependent positive inotropism (Matsuda
et al., 2004). The relevant tonic CST-induced negative inotropism
and lusitropism are attained through pertussis toxin-sensitive
(PTX), receptor-independent activation via heterotrimeric G
proteins and Gαi/o subunits. Likewise, Gi/o proteins activa-
tion could limit the Gs-mediated positive contractile effects.
The peptide signaling involves both beta2-AR and beta3-AR,
with a higher affinity for the first one (as evidenced by low
IC50 values) but not beta1-AR, being unaffected by choliner-
gic receptor inhibition, respectively (Angelone et al., 2008). It
is known that beta1-AR, coupled to Gs proteins, is responsible
for positive inotropism and lusitropism, while beta2-AR, mainly
coupled to Gi/o proteins, is responsible for the opposite effects
on contractility and relaxation (Xiao et al., 1999). Moreover,
cardiac beta2-AR/Gi stimulation can activate PI3K with conse-
quent negative inotropism (Yano et al., 2007). Interestingly, an
important component of the CST signal-transduction is rep-
resented by the PI3K/Akt/eNOS/NO/cGMP-dependent pathway,
as shown by the PI3K blockade which abolishes the peptide-
induced inotropism and lusitropism (Angelone et al., 2012b).
The CST signaling also requires an endothelium-derived bioactive
NO mechanism, since it depends from the functional integrity
of the endothelium. To further analyse the signal-transduction
mechanism of CST and its variants, Bassino et al. (2011) mea-
sured contractility and Ca2+ transients respectively on papil-
lary muscles and isolated cardiomyocytes in basal conditions
and after beta-adrenergic stimulation, evaluating on BAE-1 NO
production and eNOS phosphorylation (PSer1179eNOS). Their
data show that CST dose-dependently (5–50 nM) reduces the
effect of beta-adrenergic stimulation which, rather than result-
ing from a direct myocardial action of the peptide, depends from
a Ca2+-independent/PI3K-dependent NO release from endo-
cardial endothelial cells. Consistent with this, CST induces in
BAE-1 cells a Wortmannin-sensitive, Ca2+-independent increase
of NO production and PSer1179eNOS. The variant P370L-CST,
but not G364S-CST, exerted an anti-adrenergic effect and an
increased NO release comparable to that elicited by WT-CST.
As mentioned above (Cardiac actions of VS-1), such calcium-
independent, caveolae-mediated endocytosis mechanism for acti-
vation of Akt-PI3K-eNOS pathway, also proposed for insulin,
insulin-like growth factor-1, and estrogens, has been suggested
for VS-1 (Ramella et al., 2010 and references therein). In
agreement with the NO-sGC-cGMP-dependent signaling, in the
peptide-treated hearts cGMP was significantly increased and
at least two of its targets appeared implicated in the CST
action mechanism. One is PKG, known to depress myocar-
dial contractility by reducing both L-type Ca2+ current and
troponin C affinity for calcium (Angelone et al., 2012b). The
other target is phosphodiesterases type 2 (PDE2) (Angelone
et al., 2012b). Its selective inhibition by EHNA abrogates the
CST-induced inotropic and lusitropic effects both under basal
and stimulated (ISO) conditions, indicating a relevant PDE2
involvement. Conceptually important in the context of temporal
SAN/CGA interactions, Angelone et al. (2012a) also demon-
strated the involvement of both phospholamban (PLN) and
beta-arrestin S-nitrosylation. beta-arrestin is implicated in the
desensitization and internalization of G-protein-coupled recep-
tors (including beta1-AR), while its S-nitrosylation elicits and
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accelerates beta1-AR desensitization (Ozawa et al., 2008). PLN
controls sarcoplasmic reticulum Ca-ATPase (SERCA2a) by a
phosphorylation/dephosphorylation mechanism so that while
dephosphorylated PLN inhibits SERCA2a-dependent SR Ca2+
sequestration (Reddy et al., 1999), phosphorylated PLN at Ser16
by PKA relieves its inhibition on SERCA2a (Schmidt et al.,
2001). Thus, PLN S-nitrosylation appears a selective target of
the CST-induced NO release able to regulate SR Ca2+ fluxes
and Ca2+ availability for inotropy and lusitropy. These data
highlight a temporally tuned and more sophisticated CST-
promoted anti-beta-adrenergic cardiac modulation than previ-
ously perceived, which consists in rapid (PDE2 and PLN) and
medium-term (beta-arrestin-mediated beta1-AR desensitization)
regulatory switches. Accordingly, a PDE2-dependent short-term
signal switches off β adrenergic activity, while a medium-
term signal promotes more prolonged adrenergic counteraction
through beta-arrestin-mediated beta1-AR desensitization. In the
rat heart the coronary profile of CST appears non-univocal. CST
under basal conditions dose-dependently increases CP (max-
imum response at 200 nM) and abolishes the ISO-dependent
vasodilation; in contrast, it potently vasodilates the ET-1 pre-
constricted coronaries (Angelone et al., 2008), confirming the
vasodilation promoted by exogenous CST in human subjects
(O’Connor et al., 2002; Fung et al., 2010). Since it is known that in
mammals the stimulation of cardiac ETB subtype receptors pro-
mote an endothelium-dependent negative inotropism (Brás-Silva
and Leite-Moreira, 2005), CST signal was tested in presence of
the selective ETB antagonist BQ788. The consequent abrogation
of the ET-1- induced effects demonstrated the relevant ET-1/CST
cross talk, suggesting at the same time that the CST signal at
plasma membrane level significantly converges on the sympatho-
inhibitory NO pathway. In conclusion, this growing evidence
indicates that CST, in addition to its antihypertensive profile,
directly modulates myocardial and coronary functions under
both basal and stimulated (β-adrenergic and ET-1) conditions.
The peptide-induced negative contractility/relaxation influence,
as well as its coronary vasomotion might be viewed as relevant
components of a homeostatic counteraction against heightened
SAN over-activation, e.g., prolonged stress, HF, hypertensive car-
diomyopathy, namely, conditions characterized by a potentially
harmful spill-over of CAs, ET-1 and RAS agonists. Conceivably,
these cardiac properties of the peptide, together with its antihy-
pertensive and vasoactive profile, suggest that CST can function
as a novel autocrine-paracrine modulator cooperating with full-
length CGA and its derived VS-1 in the multilevel processes
required for cardio-circulatory homeostasis (see Figure 3A).
CARDIOPROTECTIVE INFLUENCE OF VS-1 AND CST
Reperfusion is indispensable for salvaging viable myocardium,
following an acute heart infarction. Both ischemic precondi-
tioning (PreC) and post-conditioning (PostC) have become
standard procedures for evaluating the cardioprotective abil-
ity of an agent when applied respectively before or after an
infarcting ischemia can enhance heart function recovery, lim-
iting infarct size (Hausenloy, 2009, 2012; Penna et al., 2009).
Various peptides can elicit cardioprotection, triggering both phar-
macological pre- and post-conditioning signaling pathways. In
rodents, these include the Reperfusion Injury Salvage Kinase
(RISK) and the Survivor Activating Factor Enhancement (SAFE)
pathways (Sivaraman et al., 2007; Hausenloy et al., 2011). The
actions of Survival kinases, such as phosphatidylinositol-3-kinase
(PI3K)/protein kinase B (Akt/PKB) and protein kinase C (PKC),
may converge on downstream mitochondrial targets to open
ATP-sensitive potassium (mitoKATP) channels, thereby affect-
ing cellular survival through a decrease of necrosis and apoptosis
(Zatta et al., 2006; Boengler, 2011). Cardioprotection involves
endothelial and endothelial derived NO, as well as adrenergic
components (Bell and Yellon, 2003; Pagliaro et al., 2003; Cappello
et al., 2007). The acknowledged anti-adrenergic and endothelial
PI3K-inducedNO signaling of both VS-1 and CST have addressed
several studies to verify their eventual cardioprotective profiles.
The comparison of the cardioprotective effects of VS-1 and CST
in ischemic conditioning highlights a remarkable similarity and
subtle differences. VS-1 appears to act as a pre-conditioning
inducer while CST acts as a post-conditioning agent (reviewed by
Penna et al., 2012). Human recombinant VS-1 protects against the
extension of myocardial infarction converging on PKC through
two different pathways, one mediated by adenosine A1 receptors
and the other mediated by NO release (Cappello et al., 2007).
On the other hand, the CST-induced protection reduces infarct
size and improves post-ischemic cardiac function via PI3K/Akt,
PKCs and mito-KATP channel activation, which may implicate
a ROS signaling (Perrelli et al., 2013). CST is also able to exert
direct myocardial protection via an endothelium-independent
mechanism, as shown by Penna et al. (2010) in isolated adult
cardiomyocytes exposed to simulated I/R, where the peptide has
been shown to induce a partial mitochondrial depolarization
(Perrelli et al., 2013) (see Figure 3B). Very recently, it has been
also reported that CST protects in the post-ischemic SHR heart
by increasing the expression of anti-apoptotic and pro-angiogenic
factors, supporting its potential therapeutic role, even in the pres-
ence of comorbidities, such as hypertension and cardiac hyper-
trophy (Penna et al., 2014a, June Accepted). These data are of
interest also taking into account the angiogenic properties of CST
reported by Theurl et al. (2010). A CST-induced S-nitrosylation
of calcium channels in the post-ischemic phase has been recently
reported by Penna et al. (2014a). Of note, this posttranslational
modification of a L-type calcium channel subunit has already
been described in preconditioning cardioprotection by Murphy
et al. (2014) and in non-ischemic hearts treated with CST by
Angelone et al. (2012b). The CST-Post-elicited S-nitrosylation
of calcium channel may be functionally important, since the
oxidative/nitrosative signaling is known to play a major role in
cardioprotection against ischemia/reperfusion injury in both pre-
conditioning and post-conditioning (Pagliaro et al., 2011; Tullio
et al., 2013; Penna et al., 2014b).
CARDIAC ACTIONS OF SERPININ
The recent story of serpinin began with Kim and Loh (2006)
examining the processing of the C-terminal domain of CGA in
mouse pituitary cell line, (AtT-20). They showed that a CGA
fragment, but not intact CGA, secreted in an activity-dependent
manner, increased granule biogenesis by up-regulating protease
nexin-1 (PN-1), a serine protease inhibitor protein, which then
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FIGURE 3 | Representative scheme showing the physiological
(A) and the physiopathological (B) (i.e., cardioprotection) pathways
activated by CgA-derived peptides. Cardioinhibitory effects induced by
VS1 and CST involve the NOS/NO/cGMP/PKG pathway.
Serpinin-dependent positive inotropism involves the AD/cAMP/PKA
pathway.
stabilizes granule proteins to enhance their levels in the Golgi
complex. Successively, Koshimizu et al. (2010, 2011) demon-
strated that, in AtT-20 pituitary cells, both mouse CGA435–460,
a synthetic 26 amino acid residue peptide named serpinin, and
endogenous-serpinin related peptides were able to induce PN-
1 mRNA up-regulation. In particular, they identified in AtT-
20 cell-conditioned medium a 23-mer serpinin-like fragment,
pyroglutaminated (pGlu-23Leu) serpinin, which was present in
the highest amount compared to the other serpinin-related pep-
tides serpinin (Ala26Leu), and serpinin-Arg-Arg-Gly (Ala29Gly),
(Koshimizu et al., 2011). The recognition that the serpinin region
of CGA is highly conserved in mammals suggests that pep-
tides derived from this domain may have relevant physiological
functions.
pGlu-serpinin upregulates PN-1 mRNA expression in AtT-20
cells via a cAMP-protein kinase and exerts an antiapoptotic effect
on these cells and on cultured CNS neurons exposed to oxidative
stress. Since PN-1 expression is upregulated by CGA in AtT-20
cells (Kim and Loh, 2006) and PN-1 is a potent inhibitor of
plasmin which causes apoptosis in chronically injured neurons
(Ho-Tin-Noé et al., 2009), it is possible that pGlu-serpinin can
be implicated in plasmin inhibition.
Soon after, Tota et al. (2012) demonstrated the involvement
of serpinin in heart function. Using HPLC and ELISA meth-
ods, they detected in the rat heart serpinin peptides, Ala29Gly
and pGlu-serpinin being the predominant fragments. This means
that the rodent heart is able to process the C terminal domain
of CGA as it does with its N terminal domain. Moreover, using
the Langendorff perfused rat heart to evaluate the hemodynamic
responses, Tota et al. (2012) showed that serpinin and pGlu-
serpinin dose-dependently (11–165 nM) increase inotropism and
lusitropism within the first 5min after administration. pGlu-
serpinin appears more potent than serpinin, its action start-
ing from 1 nM. These effects were corroborated by the results
obtained on the isolated rat papillary muscle preparation which
allows to measure contractility in terms of tension development
and muscle length. It was found that while pGlu-serpinin induces
positive inotropism, Ala29Gly is unaffective. Both pGlu-serpinin
and serpinin act through a beta1-Adrenergic Receptor/Adenylate
Cyclase/cAMP/PKA pathway (Tota et al., 2012), a finding of par-
ticular interest in view of the opposite beta-depressive profile
of the two CGA-derived peptides, VS-1 and CST. The beta-
adrenergic-like agonist profile of serpinin is further confirmed
by the results showing that pGlu-serpinin increases intracardiac
cAMP levels. pGlu-serpinin and serpinin at nanomolar range
act as beta 1-adrenergic-like agonists, mimicking the intracardiac
sympathetic neurotransmitters and/or circulating CAs. Like these
agents, they increase cellular levels of cAMP, thereby remark-
ably affecting myocardial mechanical performance. Namely, they
increase the rate and extent of tension development during sys-
tole (positive inotropy), hence augmenting stroke volume; at
the same time, they accelerate myocardial relaxation (positive
lusitropy), hence shortening the overall duration of diastole. As
demonstrated by the experiments on isolated papillary muscle,
the serpinin action is independent from any possible alteration
in HR and coronary flow rate, as well as from norepinephrine
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release from sympathetic nerve terminals (as demonstrated by
tyramine treatment). Studies are needed to clarify the earliest
events underpinning the transduction of the serpinin signal. Since
no receptor or direct binding partner has been so far identi-
fied for serpinin or pGlu-serpinin, on the basis of the reported
functional antagonism, Tota et al. (2012) have proposed that ser-
pinin and pGlu-serpinin may function as allosteric modulators
of the beta-adrenergic receptor independently from the ligand
binding site, thereby triggering the well-known beta-adrenergic-
induced cascade. Therefore, serpinin peptides resemble the other
CGA-derived peptides in such apparent lack of classical receptors.
According to a mechanism common for cAMP elevating ago-
nists (Koshimizu et al., 2010), serpinin and pGlu-serpinin might
bind to a G protein-coupled receptor (GPCR) enhancing the car-
diac cAMP levels, with consequent hemodynamic effects that are
indeed abolished by selective inhibition of AD and PKA. The
major downstream targets of the AD-cAMP signaling are PKAs
which phosphorylate a number of proteins, including SERCA
and its associated modulatory protein, PLN, both crucial regula-
tors of myocardial inotropy and lusitropy (Katz, 1990). SERCA-
dependent Ca++ uptake within SR promotes cation removal
during diastole, thus affecting relaxation and the subsequent con-
traction (Satoh et al., 2011). Noteworthy, blockade of SERCA
activity by thapsigargin, abolishes the pGlu-serpinin-elicited
inotropy and lusitropy. It is well known that Ca++ sensitivity for
SERCA is enhanced by PKA-induced phosphorylation of PLN,
a downstream target of the beta-adrenergic-PKA cascade which
plays a determinant role in the adreno-sympathetic modulation
of myocardial contractility/relaxation (Mattiazzi et al., 2007). It
is thus physiologically relevant that pGlu-serpinin induces PNL
phosphorylation at Ser16, residue (see Figure 3A).
PUTATIVE CARDIOPROTECTIVE INFLUENCE
The pGlu-serpinin-PKA cascade also appears to induce phos-
phorylation of ERK1/2 and GSK3beta known to mediate PGE2
and EP4 signaling in neonatal ventricular myocytes (Tota et al.,
2012 and references therein). These proteins are components of
the protective RISK (reperfusion injury signaling kinase) pathway
implicated in myocardial protection against ischemia-reperfusion
injury in rodents (Hausenloy et al., 2011) and, possibly, in
the pGlu-serpinin-induced anti-apoptotic effects against reactive
oxygen species (ROS) reported in cultured cerebral neurons by
Koshimizu et al. (2011). This observation has prompted prelim-
inary experiments aimed to test the cardioprotective influence of
serpinin against I/R injury in the rodent heart. Very recently, Tota
et al. (2012) reported that, given in pre- and post-conditioning,
pGlu-serpinin reduces infarct size and preserves the hemody-
namic function of both isolated normotensive and SHR hearts,
being more protective in the latter. Moreover, in both normoten-
sive and hypertensive hearts, pGlu-serpinin while inducing a mild
cardioprotection in pre-conditioning, exerts streaking cardiopro-
tection in post-conditioning. All these effects appear to involve
the protective RISK pathway (Tota et al., 2012) (see Figure 3B).
In conclusion, the recent recognition that the C termi-
nal domain of CGA can generate in the heart serpinin frag-
ments that enhance myocardial contractility/relaxation through
beta1-adrenergic/AD/cAMP signaling adds new evidence to the
sympatho-chromaffin profile of CGA. It is likely that in response
to perturbed conditions, a tissue-specific and spatio-temporally
concerted processing of CGA can produce counter-regulatory
peptides able to reset cardio-circulatory homeostasis through
“whip-brake” networks (see Figure 4). It might be expected that
such ability of CGA and its derived VS-1, CST and serpinin could
be differentially regulated in relation to short- or long-term acti-
vation of SAN, but this issue is still a closed book. In this context,
the evidence that pGlu-serpinin acts on beta1-AR in a functional
manner, i.e., independent of a direct classical interaction with
AR active site, may be of putative therapeutical interest, being
an alternative to direct adreno-receptor stimulation when this
can be undesirable. In fact, it is known that prolonged, long-
term beta-AR stimulation can directly inducemaladaptive cardiac
hypertrophy, eventually, leading to HF.
CONCLUSIONS AND PERSPECTIVES
Studies in the past 15 years have convincingly revealed the cardio-
vascular activities of CGA and its derived peptides VS-1, CST and
serpinin, along with their striking adreno-sympathetic regulatory
influences (see Table 1). This knowledge, which has widened the
prohormone/cytokine profile of CGA, has been paralleled and
integrated by a growing number of clinical studies that have doc-
umented the biomedical implications of CGA and its peptides
(especially the antihypertensive CST) in various cardiovascular
diseases, particularly in relation to their diagnostic and prog-
nostic value. It is well known that conditions characterized by
perturbed cardio-circulatory homeostasis, especially in the case of
severe heart diseases (i.e., myocardial infarction, acute coronary
syndromes, ventricular hypertrophy), activate complex neuro-
humoral networks (SAN and NPs, to mention two), finely inte-
grated at both local and systemic levels, that tend to re-establish
the constancy of the internal milieu (Angelone et al., 2012a and
references therein). As illustrated in this review, the available evi-
dence strongly supports the view that CGA and its cardiotropic
FIGURE 4 | Representative picture showing the ability of CgA-derived
peptides to reset cardio-circulatory homeostasis through
“whip-brake” networks in response to perturbed conditions. A
tissue-specific and spatio-temporally concerted processing of CGA can
generate counter-regulatory peptides able to reset cardio-circulatory
homeostasis through “whip-brake” networks.
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Table 1 | Synopsis of the cardiac effects of CgA and its derived peptides.
Peptide Tissue Contractility/ Heart rate Vasoactivity Doses Adrenergic References
Relaxation Stimulation
CgA Ex vivo rat heart Reduction No changes Vasodilation 1 pM ÷ 4nM - Pasqua et al.,
2013
VS1 Ex vivo rat heart Reduction No changes No changes 11 ÷ 165nM Non-competitive
Antagonism
Cerra et al., 2008
rCGA1-64 Ex vivo rat heart
Rat Papillary
muscles
Reduction No changes Vasodilation 33 ÷ 165 nM
10 ÷ 100 nM
Non-competitive
Antagonism
Cerra et al., 2008




Serpinin Ex vivo rat heart
Rat Papillary
muscles




Tota et al., 2012
fragments represent an important component of these neuroen-
docrine networks, challenging cross-disciplinary contributions in
this direction. However, the excitement that accompanies this
new knowledge is paired with a deeper perception of the many
questions that need to be clarified. We neither know to which
extent the extensive ex vivo evidence can be extrapolated to the
in vivo situation, nor if the peptide-induced cardiac actions are
beneficial for the diseased heart or they may concur to aggra-
vate its pathology. For example, in acute coronary syndromes
the vasodilatory, negative inotropic and lusitropic properties, and
the anti-adrenergic effect elicited by the two CGA fragment VS-
1 and CST, might be either detrimental, thus contributing to HF
development, or compensatory, at least at the beginning of the
pathology (Kubota, 1997). Similarly, in the context of circulatory
homeostasis, there is a need to deepen the potential beneficial
role of the CGA/NO axis in relation to the CGA-induced “anti-
inflammatory” ability and protection of the endothelial barrier
against TNF-alpha-induced vascular permeability (Ferrero et al.,
2002). At the same time, an open window remains concerning the
putative value of CGA and its fragments as cardiovascular diag-
nostic/prognostic biomarkers. In this regard, caution is especially
needed because of two main reasons. The first is to understand
whether these peptides provide incremental information with
respect to conventional biomarkers. The second is to prevent
errors in evaluating CGA and its fragments in biological sam-
ples by developing appropriate and sensitive methods for their
detection and measurements, excluding interference induced by
food intake and drug therapies (i.e., proton pump inhibitors, H2
antagonists, and glucocorticoids (Giusti et al., 2004).
The following years will tell us how can our existing view of
CGA biology be modified in face of the new discoveries and how
are we to deal with the cross-disciplinary challenges provided by
the upcoming research.
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